Solid Biosciences Inc. (SLDB)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy's Limitations
Solid Biosciences is a speculative buy, leveraging a differentiated SGT-003 gene therapy for Duchenne muscular dystrophy with a credible cash runway into mid-2028. SLDB's investment thesis centers on building both biological and controlled functional evidence, not just microdystrophin expression, to address physician and regulatory concerns. Competitive positioning against Sarepta and Regenxbio hinges on achieving clinically meaningful differentiation in function, safety, and eligibility, with time pressure from advancing rivals.
Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Ally Bridge Group NY LLC Has $3.39 Million Stock Position in Solid Biosciences Inc. $SLDB
Ally Bridge Group NY LLC cut its stake in shares of Solid Biosciences Inc. (NASDAQ: SLDB) by 24.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 549,182 shares of the company's stock after selling 174,818 shares during
Solid Biosciences Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 150 | $1,420.5 | $819.75 | -$600.75 | -42.29% |
| NA Nizar Araji National Bank Of Canada /FI/ | 31 | $293.57 | $177.94 | -$115.63 | -39.39% |
| BG Bart Gancher Intech Investment Management LLC | 16,302 | $82,885.77 | $93,573.48 | $10,687.71 | 12.89% |
| CD Charlie Durham Sterling Capital Management LLC | 949 | $5,855.43 | $5,186.28 | -$669.15 | -11.43% |
 Anthony Scaramucci SkyBridge Capital II LLC | 4.28M | $29.15M | $23.98M | -$5.17M | -17.74% |
Solid Biosciences Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Kristen Kluska Cantor Fitzgerald | 5,626.76 | $56,999.08 | $31,537.99 | -$25,461.09 | -44.67% |
 Danielle Brill Truist Securities | 5,765.13 | $53,731 | $32,169.42 | -$21,561.58 | -40.13% |
Solid Biosciences Inc. (SLDB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Solid Biosciences Inc. ever had a stock split?
Solid Biosciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Alexander G. Cumbo CEO | NASDAQ (NGS) Exchange | 83422E204 CUSIP |
| US Country | 121 Employees | - Last Dividend | 28 Oct 2022 Last Split | 26 Jan 2018 IPO Date |
Overview
Solid Biosciences Inc. is a pioneering life science company based in the United States, focusing on the discovery and development of novel therapies for a range of neuromuscular and cardiac diseases. Since its inception in 2013, the company has committed itself to addressing some of the most challenging medical conditions with significant unmet needs. Headquartered in Charlestown, Massachusetts, Solid Biosciences has established collaborations and licensing agreements with major institutions such as Ultragenyx Pharmaceutical Inc., University of Washington, University of Missouri, and University of Florida. Through these partnerships, the company aims to leverage cutting-edge research and technological advancements to bring transformative treatments to patients worldwide.
Products and Services
At the core of Solid Biosciences' portfolio are innovative gene therapy candidates and technologies designed to combat rare and debilitating diseases:
- SGT-003: A cutting-edge gene transfer candidate developed for the treatment of Duchenne muscular dystrophy, a severe form of muscular degeneration and weakness.
- SGT-501: Aimed at treating Catecholaminergic Polymorphic Ventricular Tachycardia, SGT-501 represents a breakthrough in cardiac disease management, addressing a condition characterized by an abnormal heart rhythm.
- AVB-401: This candidate focuses on the treatment of BAG3-mediated dilated cardiomyopathy, a cardiac disorder that leads to heart enlargement and impaired pumping ability.
- SGT-601: Developed to treat a rare cardiac condition caused by mutations in the gene coding for the cardiac troponin T protein, which is crucial for heart muscle contraction coordination.
- SGT-701: Targets a rare inherited disease resulting from mutations in the RBM20 gene, which is a cardiac splicing factor that regulates alternative splicing and codes for the RNA binding motif protein 20, involved in cardiac function.
- AVB-202-TT: A gene therapy approach for Friedreich's ataxia, a disease characterized by progressive damage to the nervous system and movement problems.
In addition to these candidates, Solid Biosciences is also advancing platform technologies such as capsid libraries and dual gene expression systems. These technologies are designed for the efficient delivery and expression of gene therapies, potentially enabling the packaging of multiple transgenes into one capsid for more effective treatment strategies. Through its innovative approach to drug development and its commitment to fighting rare diseases, Solid Biosciences Inc. stands at the forefront of genetic and cellular therapies, aiming to transform the lives of patients around the globe.
Contact Information
